Page last updated: 2024-12-05

succinylacetone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Succinylacetone, also known as 2,5-hexanedione, is a naturally occurring compound found in various plants and animal tissues. It is a colorless, oily liquid with a sweet odor. It can be synthesized through various chemical reactions, such as the condensation of acetoacetic ester with ethyl acetate or the oxidation of 2,5-hexanediol. Succinylacetone plays a significant role in the biosynthesis of porphyrins, essential molecules for hemoglobin and other important biological functions. It acts as an inhibitor of δ-aminolevulinate dehydratase (ALAD), an enzyme involved in the heme biosynthesis pathway. This inhibition can lead to the accumulation of δ-aminolevulinate (ALA) and porphobilinogen (PBG), two precursors of porphyrins, in the body. Accumulation of these precursors can lead to various health issues, including porphyrias. Succinylacetone is also known to exhibit cytotoxic and antiproliferative activities, making it a subject of research for potential therapeutic applications in areas like cancer treatment. The compound's ability to inhibit ALAD and its potential cytotoxic properties make it an important target for studying its role in porphyria development and its therapeutic potential. Furthermore, the compound's presence in various biological systems and its involvement in the biosynthesis of essential molecules make it a subject of ongoing research in diverse fields, including biochemistry, medicine, and environmental science.'

succinylacetone: inhibitor of heme biosynthesis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4,6-dioxoheptanoic acid : A dioxo monocarboxylic acid that is heptanoic acid in which oxo groups replace the hydrogens at positions 4 and 6. It is an abnormal metabolite of the tyrosine metabolic pathway and a marker for type 1 tyrosinaemia. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5312
CHEMBL ID222824
CHEBI ID87897
SCHEMBL ID503918
MeSH IDM0074952

Synonyms (53)

Synonym
51568-18-4
heptanoic acid,6-dioxo-
nsc174804
nsc-174804
DIVK1C_006800
NCI60_001428
SPECTRUM_001999
NCGC00178670-01
BSPBIO_002406
4,6-dioxoheptanoic acid
succinylacetone
4,6-dioxoheptanoic acid, powder
ccris 1387
nsc 174804
succinyl acetone
heptanoic acid, 4,6-dioxo-
KBIO3_001626
KBIO1_001744
KBIOGR_001852
KBIO2_002565
KBIOSS_002574
KBIO2_007701
KBIO2_005133
KBIOGR_001778
SPBIO_000574
SPECTRUM2_000467
SPECTRUM4_001266
SPECTRUM4_001249
SPECTRUM3_000763
SPECPLUS_000704
bdbm50197063
CHEMBL222824 ,
chebi:87897 ,
4,6-dioxoheptanoate
AKOS006282601
kz0kv2q190 ,
unii-kz0kv2q190
CCG-39960
FT-0674728
FT-0674727
SCHEMBL503918
mfcd00002797
DTXSID50199519
AS-57899
HY-W010184
CS-W010900
BCP17098
Q25324500
YSWG260
AMY13893
H10298
BCA56818
U0127

Research Excerpts

Overview

Succinylacetone was known to be a toxic metabolite of tyrosine in human and animals. Its existence in plant was unclear though the metabolic disturbance of Tyrosine was also found in plant. Succinyl acetone is a specific marker for the inherited metabolic disease, hepatorenal tyrosinemia.

ExcerptReferenceRelevance
"Succinylacetone is an inhibitor of δ-aminolevulinic acid (ALA) dehydratase (ALAD), which is involved in chlorophyll (Chl) biosynthesis."( Loss of fumarylacetoacetate hydrolase causes light-dependent increases in protochlorophyllide and cell death in Arabidopsis.
Qiu, B; Ren, C; Xiong, X; Zhi, T; Zhou, Z; Zhu, Q, 2019
)
1.24
"Succinylacetone was known to be a toxic metabolite of tyrosine in human and animals caused by blockage of the final step in tyrosine degradation pathway, but its existence in plant was unclear though the metabolic disturbance of tyrosine was also found in plant. "( A GC/MS method for determination of succinylacetone in Arabidopsis thaliana.
Qiu, B; Ren, C; Wang, X; Yang, Z; Zhi, T; Zhou, L; Zhou, Z, 2016
)
2.15
"Succinylacetone (SA) is a specific marker for the inherited metabolic disease, hepatorenal tyrosinemia. "( Determination of succinylacetone in dried blood spots and liquid urine as a dansylhydrazone by liquid chromatography tandem mass spectrometry.
Al-Ahaidib, LY; Al-Dirbashi, OY; Al-Hassnan, Z; Al-Sayed, MM; Brink, HJ; Faqeih, E; Filimban, N; Jacob, M; Jakobs, C; Rashed, MS, 2006
)
2.12
"Succinylacetone (SUAC) is a specific marker for TYR 1 but not detectable by routine newborn screening."( Quantitative determination of succinylacetone in dried blood spots for newborn screening of tyrosinemia type I.
Goodman, SI; Gunawardena, ND; Hahn, SH; Magera, MJ; Matern, D; Mitchell, GA; Rinaldo, P; Tortorelli, S, 2006
)
1.34
"Succinylacetone (SA) is an inhibitor of heme synthesis that acts on the enzyme delta-aminolevulinic acid dehydratase. "( Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: examination of the intermediates involved in iron metabolism.
Ponka, P; Richardson, DR; Vyoral, D, 1996
)
1.96
"Succinylacetone (SA) proved to be a potent inhibitor of in vitro lymphoproliferative responses. "( Inhibition of human lymphoproliferative responses and altered lymphocyte membrane phenotype by succinylacetone.
Blaese, RM; Hess, RA; Jackson, MO; Leichtling, KD; Weaver, LD; Winkelstein, A,
)
1.79
"Succinylacetone (SA) is a known inhibitor of the heme biosynthetic pathway in liver. "( delta-Aminolevulinic acid dehydratase: effects of succinylacetone in rat liver and kidney in an in vivo model of the renal Fanconi syndrome.
Carter, BE; Roth, KS; Wyss, PA, 1992
)
1.98
"Succinylacetone is a weaker inhibitor of heme biosynthesis than CoCl2, 3-amino-1,2,4-triazole, or thioacetamide used earlier in this laboratory."( Involvement of heme in the transcriptional activation of CYPIIB1/B2 gene by phenobarbitone in rat liver--studies with succinylacetone.
Padmanaban, G; Venkateswar, V, 1991
)
1.21
"Succinylacetone (SA) is known to be a potent inhibitor of delta-aminolevulinic acid dehydratase (ALAD) in the liver. "( delta-Aminolevulinic acid dehydratase: is there a form unique to renal cortex?
Carter, BE; Moses, LC; Roth, KS; Spencer, PD, 1990
)
1.72
"Succinylacetone is a seven-carbon organic ketoacid that we have previously shown to inhibit tumor allograft rejection as well as the primary antibody response to sheep erythrocytes in rats. "( Immunosuppression by succinylacetone. II. Prevention of graft-vs-host disease.
Blaese, RM; Hess, RA; Tschudy, DP, 1987
)
2.03

Actions

Succinylacetone was shown to reduce cellular heme and porphyrins. It was also shown to induce delta-aminolevulinate synthase in chick embryo liver cells.

ExcerptReferenceRelevance
"Succinylacetone was shown to inhibit aminolevulinate dehydratase (5-aminolevulinate hydro-lyase (adding 5-aminolevulinate and cyclizing), EC 4.2.1.24) to reduce cellular heme and porphyrins and to induce delta-aminolevulinate synthase (succinyl-CoA:glycine C-succinyltransferase (decarboxylating), EC 2.3.1.37) in monolayers of chick embryo liver cells. "( The effects of succinylacetone (4,6-dioxoheptanoic acid) on delta-aminolevulinate synthase activity and the content of heme in monolayers of chick embryo liver cells.
Atsmon, A; Epstein, O; Greenblat, Y; Schoenfeld, N, 1982
)
2.06
"When succinylacetone is used to inhibit Belgrade heme synthesis, iron from diferric transferrin does not accumulate in the stromal fraction that contains mitochondria, nor does 59Fe accumulate in the nonheme cytosolic fraction."( Iron distribution in Belgrade rat reticulocytes after inhibition of heme synthesis with succinylacetone.
Cohan, DS; Garrick, LM; Garrick, MD; Gniecko, K; Grasso, JA; Liu, Y, 1993
)
0.96

Treatment

In succinylacetone-treated cells 59Fe accumulates in a fraction containing plasma membranes and mitochondria. Treating succinyl acetone with hydroxylamine hydrochloride at a pH of less than 5 caused formation of a derivative separated by capillary gas chromatography.

ExcerptReferenceRelevance
"In succinylacetone-treated cells 59Fe accumulates in a fraction containing plasma membranes and mitochondria as well as cytosol ferritin and an unidentified low molecular weight fraction obtained by Sephacryl S-200 chromatography."( Iron utilization in rabbit reticulocytes. A study using succinylacetone as an inhibitor or heme synthesis.
Ponka, P; Schulman, HM; Wilczynska, A, 1982
)
1.02
"Treating succinylacetone with hydroxylamine hydrochloride at a pH of less than 5 caused formation of a derivative separated by capillary gas chromatography into two isomers: 3-methyl-5- isoxazole propionate and 5-methyl-3- isoxazole propionate as their trimethylsilyl derivatives (molecular weight 227)."( Determination of urinary succinylacetone by capillary gas chromatography.
Bowers, LD; Fregien, KD; Krivit, W; Ramnaraine, ML; Tuchman, M; Whitley, CB, 1984
)
0.96

Bioavailability

ExcerptReferenceRelevance
" bioavailability was ca."( Suppression of graft-versus-host disease by succinyl acetone in a rat allogeneic bone marrow transplantation model.
Bauer, R; Chang, TQ; Fidler, JM; Vitt, CR; Young, JD, 1993
)
0.29

Dosage Studied

ExcerptRelevanceReference
" Three intervals of treatment with this dose rate were used (Day 0-7, Day 7-14, or Day 0-14) and, regardless of dosage interval, suppression of the disease was complete."( Treatment of experimental autoimmune uveitis in the rat with systemic succinylacetone.
Blaese, RM; Hess, RA; Nussenblatt, RB; Palestine, AG; Skolik, SA, 1988
)
0.51
" Dose-response studies showed that SA (250 microM) did not affect cell viability or growth up to 72 h, but resulted in inhibition of ALA-D activity (> 93%) and decreased cellular levels of both heme and MPO (approximately 25% of control)."( The post-translational processing of myeloperoxidase is regulated by the availability of heme.
Bonkovsky, HL; Guzman, GS; Kinkade, JM; Pinnix, IB; Zaki, SR, 1994
)
0.29
" To increase sensitivity, analytes were extracted from liver, urine, plasma and cultured nerve cells before and after dosing with DCA, derivatized to their pentafluorobenzyl esters, and analyzed via GC-MS/MS."( A GC-MS/MS method for the quantitative analysis of low levels of the tyrosine metabolites maleylacetone, succinylacetone, and the tyrosine metabolism inhibitor dichloroacetate in biological fluids and tissues.
Henderson, GN; Jia, M; Liu, H; Stacpoole, PW; Zolodz, MD, 2006
)
0.55
" These data show a dose-response increase in HPRT-Mf in HL-60 cells treated with SA, suggesting that this chemical causes mutations in the HPRT locus in these cells either directly or indirectly through its inhibition of the MPO activity."( Increased mutant frequencies in the HPRT gene locus of leukemia HL-60 cells treated with succinylacetone.
Kagan, VE; Keohavong, P; Yalowich, JC; Zheng, KC, 2006
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
beta-diketoneA diketone in which the two keto groups are separated by a single carbon atom.
dioxo monocarboxylic acidAny monocarboxylic acid containing two ketonic or aldehydic oxo groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Tyrosine metabolism and related disorders724

Protein Targets (8)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Lysine-specific demethylase 4EHomo sapiens (human)IC50 (µMol)23.90000.20001.95696.3096AID698697
Lysine-specific demethylase 6BHomo sapiens (human)IC50 (µMol)16.50000.01601.66726.9000AID698695
Gamma-butyrobetaine dioxygenaseHomo sapiens (human)IC50 (µMol)100.00000.69003.16457.9000AID698692
Lysine-specific demethylase 5CHomo sapiens (human)IC50 (µMol)4.50000.16002.68377.9433AID698696
Egl nine homolog 1Homo sapiens (human)IC50 (µMol)59.00000.00701.86148.0000AID440674; AID698694
Hypoxia-inducible factor 1-alpha inhibitorHomo sapiens (human)IC50 (µMol)100.00008.60008.60008.6000AID698693
Histone lysine demethylase PHF8Homo sapiens (human)IC50 (µMol)2.30000.21001.36203.2000AID698701
Lysine-specific demethylase 2AHomo sapiens (human)IC50 (µMol)0.57000.16002.45966.9000AID698700
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (48)

Processvia Protein(s)Taxonomy
regulation of gene expressionLysine-specific demethylase 4EHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 4EHomo sapiens (human)
inflammatory response to antigenic stimulusLysine-specific demethylase 6BHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 6BHomo sapiens (human)
response to activityLysine-specific demethylase 6BHomo sapiens (human)
hippocampus developmentLysine-specific demethylase 6BHomo sapiens (human)
cell fate commitmentLysine-specific demethylase 6BHomo sapiens (human)
endothelial cell differentiationLysine-specific demethylase 6BHomo sapiens (human)
positive regulation of transcription by RNA polymerase IILysine-specific demethylase 6BHomo sapiens (human)
mesodermal cell differentiationLysine-specific demethylase 6BHomo sapiens (human)
cardiac muscle cell differentiationLysine-specific demethylase 6BHomo sapiens (human)
response to fungicideLysine-specific demethylase 6BHomo sapiens (human)
cellular response to hydrogen peroxideLysine-specific demethylase 6BHomo sapiens (human)
positive regulation of cold-induced thermogenesisLysine-specific demethylase 6BHomo sapiens (human)
heart developmentLysine-specific demethylase 6BHomo sapiens (human)
regulation of gene expressionLysine-specific demethylase 6BHomo sapiens (human)
carnitine biosynthetic processGamma-butyrobetaine dioxygenaseHomo sapiens (human)
response to toxic substanceLysine-specific demethylase 5CHomo sapiens (human)
negative regulation of DNA-templated transcriptionLysine-specific demethylase 5CHomo sapiens (human)
rhythmic processLysine-specific demethylase 5CHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 5CHomo sapiens (human)
regulation of DNA-templated transcriptionLysine-specific demethylase 5CHomo sapiens (human)
response to hypoxiaEgl nine homolog 1Homo sapiens (human)
intracellular iron ion homeostasisEgl nine homolog 1Homo sapiens (human)
intracellular oxygen homeostasisEgl nine homolog 1Homo sapiens (human)
negative regulation of DNA-binding transcription factor activityEgl nine homolog 1Homo sapiens (human)
regulation of angiogenesisEgl nine homolog 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIEgl nine homolog 1Homo sapiens (human)
negative regulation of cyclic-nucleotide phosphodiesterase activityEgl nine homolog 1Homo sapiens (human)
cardiac muscle tissue morphogenesisEgl nine homolog 1Homo sapiens (human)
heart trabecula formationEgl nine homolog 1Homo sapiens (human)
ventricular septum morphogenesisEgl nine homolog 1Homo sapiens (human)
labyrinthine layer developmentEgl nine homolog 1Homo sapiens (human)
response to nitric oxideEgl nine homolog 1Homo sapiens (human)
regulation of modification of postsynaptic structureEgl nine homolog 1Homo sapiens (human)
regulation protein catabolic process at postsynapseEgl nine homolog 1Homo sapiens (human)
peptidyl-proline hydroxylation to 4-hydroxy-L-prolineEgl nine homolog 1Homo sapiens (human)
cellular response to hypoxiaEgl nine homolog 1Homo sapiens (human)
positive regulation of myoblast differentiationHypoxia-inducible factor 1-alpha inhibitorHomo sapiens (human)
negative regulation of Notch signaling pathwayHypoxia-inducible factor 1-alpha inhibitorHomo sapiens (human)
negative regulation of DNA-templated transcriptionHypoxia-inducible factor 1-alpha inhibitorHomo sapiens (human)
positive regulation of vasculogenesisHypoxia-inducible factor 1-alpha inhibitorHomo sapiens (human)
G1/S transition of mitotic cell cycleHistone lysine demethylase PHF8Homo sapiens (human)
chromatin remodelingHistone lysine demethylase PHF8Homo sapiens (human)
brain developmentHistone lysine demethylase PHF8Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone lysine demethylase PHF8Homo sapiens (human)
positive regulation of transcription by RNA polymerase IHistone lysine demethylase PHF8Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone lysine demethylase PHF8Homo sapiens (human)
negative regulation of rDNA heterochromatin formationHistone lysine demethylase PHF8Homo sapiens (human)
regulation of transcription by RNA polymerase IIHistone lysine demethylase PHF8Homo sapiens (human)
protein demethylationHistone lysine demethylase PHF8Homo sapiens (human)
double-strand break repair via nonhomologous end joiningLysine-specific demethylase 2AHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 2AHomo sapiens (human)
negative regulation of transcription by competitive promoter bindingLysine-specific demethylase 2AHomo sapiens (human)
circadian regulation of gene expressionLysine-specific demethylase 2AHomo sapiens (human)
regulation of circadian rhythmLysine-specific demethylase 2AHomo sapiens (human)
protein demethylationLysine-specific demethylase 2AHomo sapiens (human)
regulation of transcription by RNA polymerase IILysine-specific demethylase 2AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (41)

Processvia Protein(s)Taxonomy
metal ion bindingLysine-specific demethylase 4EHomo sapiens (human)
histone H3K9me2/H3K9me3 demethylase activityLysine-specific demethylase 4EHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific demethylase 4EHomo sapiens (human)
protein bindingLysine-specific demethylase 6BHomo sapiens (human)
beta-catenin bindingLysine-specific demethylase 6BHomo sapiens (human)
histone demethylase activityLysine-specific demethylase 6BHomo sapiens (human)
metal ion bindingLysine-specific demethylase 6BHomo sapiens (human)
histone H3K27me2/H3K27me3 demethylase activityLysine-specific demethylase 6BHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingLysine-specific demethylase 6BHomo sapiens (human)
chromatin DNA bindingLysine-specific demethylase 6BHomo sapiens (human)
iron ion bindingGamma-butyrobetaine dioxygenaseHomo sapiens (human)
protein bindingGamma-butyrobetaine dioxygenaseHomo sapiens (human)
zinc ion bindingGamma-butyrobetaine dioxygenaseHomo sapiens (human)
gamma-butyrobetaine dioxygenase activityGamma-butyrobetaine dioxygenaseHomo sapiens (human)
identical protein bindingGamma-butyrobetaine dioxygenaseHomo sapiens (human)
DNA bindingLysine-specific demethylase 5CHomo sapiens (human)
protein bindingLysine-specific demethylase 5CHomo sapiens (human)
zinc ion bindingLysine-specific demethylase 5CHomo sapiens (human)
histone demethylase activityLysine-specific demethylase 5CHomo sapiens (human)
histone H3K4 demethylase activityLysine-specific demethylase 5CHomo sapiens (human)
histone H3K4me/H3K4me2/H3K4me3 demethylase activityLysine-specific demethylase 5CHomo sapiens (human)
protein bindingEgl nine homolog 1Homo sapiens (human)
ferrous iron bindingEgl nine homolog 1Homo sapiens (human)
2-oxoglutarate-dependent dioxygenase activityEgl nine homolog 1Homo sapiens (human)
enzyme bindingEgl nine homolog 1Homo sapiens (human)
L-ascorbic acid bindingEgl nine homolog 1Homo sapiens (human)
peptidyl-proline dioxygenase activityEgl nine homolog 1Homo sapiens (human)
hypoxia-inducible factor-proline dioxygenase activityEgl nine homolog 1Homo sapiens (human)
peptidyl-proline 4-dioxygenase activityEgl nine homolog 1Homo sapiens (human)
transcription corepressor activityHypoxia-inducible factor 1-alpha inhibitorHomo sapiens (human)
Notch bindingHypoxia-inducible factor 1-alpha inhibitorHomo sapiens (human)
protein bindingHypoxia-inducible factor 1-alpha inhibitorHomo sapiens (human)
ferrous iron bindingHypoxia-inducible factor 1-alpha inhibitorHomo sapiens (human)
zinc ion bindingHypoxia-inducible factor 1-alpha inhibitorHomo sapiens (human)
oxygen sensor activityHypoxia-inducible factor 1-alpha inhibitorHomo sapiens (human)
carboxylic acid bindingHypoxia-inducible factor 1-alpha inhibitorHomo sapiens (human)
peptidyl-histidine dioxygenase activityHypoxia-inducible factor 1-alpha inhibitorHomo sapiens (human)
[protein]-asparagine 3-dioxygenase activityHypoxia-inducible factor 1-alpha inhibitorHomo sapiens (human)
protein homodimerization activityHypoxia-inducible factor 1-alpha inhibitorHomo sapiens (human)
NF-kappaB bindingHypoxia-inducible factor 1-alpha inhibitorHomo sapiens (human)
peptidyl-aspartic acid 3-dioxygenase activityHypoxia-inducible factor 1-alpha inhibitorHomo sapiens (human)
ankyrin repeat bindingHypoxia-inducible factor 1-alpha inhibitorHomo sapiens (human)
chromatin bindingHistone lysine demethylase PHF8Homo sapiens (human)
iron ion bindingHistone lysine demethylase PHF8Homo sapiens (human)
protein bindingHistone lysine demethylase PHF8Homo sapiens (human)
zinc ion bindingHistone lysine demethylase PHF8Homo sapiens (human)
2-oxoglutarate-dependent dioxygenase activityHistone lysine demethylase PHF8Homo sapiens (human)
histone demethylase activityHistone lysine demethylase PHF8Homo sapiens (human)
histone H3K9 demethylase activityHistone lysine demethylase PHF8Homo sapiens (human)
methylated histone bindingHistone lysine demethylase PHF8Homo sapiens (human)
histone H4K20 demethylase activityHistone lysine demethylase PHF8Homo sapiens (human)
histone H3K36 demethylase activityHistone lysine demethylase PHF8Homo sapiens (human)
histone H3K27me2/H3K27me3 demethylase activityHistone lysine demethylase PHF8Homo sapiens (human)
histone H3K36me/H3K36me2 demethylase activityHistone lysine demethylase PHF8Homo sapiens (human)
histone H3K9me/H3K9me2 demethylase activityHistone lysine demethylase PHF8Homo sapiens (human)
transcription coregulator activityHistone lysine demethylase PHF8Homo sapiens (human)
protein bindingLysine-specific demethylase 2AHomo sapiens (human)
zinc ion bindingLysine-specific demethylase 2AHomo sapiens (human)
histone demethylase activityLysine-specific demethylase 2AHomo sapiens (human)
unmethylated CpG bindingLysine-specific demethylase 2AHomo sapiens (human)
histone H3K36 demethylase activityLysine-specific demethylase 2AHomo sapiens (human)
histone H3K36me/H3K36me2 demethylase activityLysine-specific demethylase 2AHomo sapiens (human)
transcription coregulator activityLysine-specific demethylase 2AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (15)

Processvia Protein(s)Taxonomy
nucleusLysine-specific demethylase 4EHomo sapiens (human)
nucleoplasmLysine-specific demethylase 4EHomo sapiens (human)
chromatinLysine-specific demethylase 4EHomo sapiens (human)
nucleusLysine-specific demethylase 4EHomo sapiens (human)
nucleusLysine-specific demethylase 6BHomo sapiens (human)
nucleoplasmLysine-specific demethylase 6BHomo sapiens (human)
MLL3/4 complexLysine-specific demethylase 6BHomo sapiens (human)
cytosolGamma-butyrobetaine dioxygenaseHomo sapiens (human)
extracellular exosomeGamma-butyrobetaine dioxygenaseHomo sapiens (human)
mitochondrionGamma-butyrobetaine dioxygenaseHomo sapiens (human)
nucleusLysine-specific demethylase 5CHomo sapiens (human)
nucleoplasmLysine-specific demethylase 5CHomo sapiens (human)
cytosolLysine-specific demethylase 5CHomo sapiens (human)
nucleusLysine-specific demethylase 5CHomo sapiens (human)
chromatinLysine-specific demethylase 5CHomo sapiens (human)
cytoplasmEgl nine homolog 1Homo sapiens (human)
cytosolEgl nine homolog 1Homo sapiens (human)
postsynaptic densityEgl nine homolog 1Homo sapiens (human)
intracellular membrane-bounded organelleEgl nine homolog 1Homo sapiens (human)
glutamatergic synapseEgl nine homolog 1Homo sapiens (human)
nucleusEgl nine homolog 1Homo sapiens (human)
cytoplasmEgl nine homolog 1Homo sapiens (human)
nucleusHypoxia-inducible factor 1-alpha inhibitorHomo sapiens (human)
nucleoplasmHypoxia-inducible factor 1-alpha inhibitorHomo sapiens (human)
cytoplasmHypoxia-inducible factor 1-alpha inhibitorHomo sapiens (human)
cytosolHypoxia-inducible factor 1-alpha inhibitorHomo sapiens (human)
perinuclear region of cytoplasmHypoxia-inducible factor 1-alpha inhibitorHomo sapiens (human)
cytoplasmHypoxia-inducible factor 1-alpha inhibitorHomo sapiens (human)
nucleusHistone lysine demethylase PHF8Homo sapiens (human)
nucleoplasmHistone lysine demethylase PHF8Homo sapiens (human)
nucleolusHistone lysine demethylase PHF8Homo sapiens (human)
nuclear membraneHistone lysine demethylase PHF8Homo sapiens (human)
nucleoplasmLysine-specific demethylase 2AHomo sapiens (human)
chromosomeLysine-specific demethylase 2AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID698696Inhibition of human KDM5C catalytic domain expressed in Sf9 cells using methyl lysine peptide substrate by AlphaScreen assay2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID278577Inhibition of Plasmodium falciparum FCK2 growth as [3H]hypoxanthine uptake after 96 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID698701Inhibition of human PHF8 expressed in Escherichia coli using methyl lysine peptide substrate by AlphaScreen assay2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID278576Inhibition of Plasmodium falciparum FCK2 growth as [3H]hypoxanthine uptake after 48 hrs2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum.
AID698693Inhibition of human FIH expressed in Escherichia coli by MALDI assay2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID440674Inhibition of human PHD2 catalytic domain (181-426) by FRET assay2009Bioorganic & medicinal chemistry letters, Nov-01, Volume: 19, Issue:21
2-Oxoglutarate analogue inhibitors of prolyl hydroxylase domain 2.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID698698Inhibition of human KDM3A catalytic domain expressed in Sf9 cells methyl lysine peptide substrate by AlphaScreen assay2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID698694Inhibition of human PHD2 expressed in Escherichia coli by fluorescence based assay2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID278589Reduced apicoplast DNA/nuclear DNA ratio in Plasmodium falciparum FCK2 at 1 mM after 72 hrs by competitive PCR2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum.
AID698695Inhibition of human KDM6B catalytic domain expressed in Escherichia coli using methyl lysine peptide substrate by AlphaScreen assay2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID698697Inhibition of human KDM4E expressed in Escherichia coli using methyl lysine peptide substrate by AlphaScreen assay2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID698692Inhibition of human BBOX1 by fluorescence based assay2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID698700Inhibition of human KDM2A expressed in Escherichia coli using methyl lysine peptide substrate by AlphaScreen assay2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (240)

TimeframeStudies, This Drug (%)All Drugs %
pre-199066 (27.50)18.7374
1990's64 (26.67)18.2507
2000's53 (22.08)29.6817
2010's56 (23.33)24.3611
2020's1 (0.42)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.58 (24.57)
Research Supply Index5.53 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index61.03 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.40%)5.53%
Reviews8 (3.21%)6.00%
Case Studies30 (12.05%)4.05%
Observational0 (0.00%)0.25%
Other210 (84.34%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]